Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis
01 Dec 2022
Drug ApprovalImmunotherapy
NEW YORK, Dec. 1, 2022 /PRNewswire/ --
Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs). The disorders are largely classified as motor neuron diseases, hereditary ataxias, peripheral nerve disorders, neuromuscular junction transmission disorders, and myopathies.
Read the full report: https://www.reportlinker.com/p06368651/?utm_source=PRN
NMDs present significant clinical challenges because of disease heterogeneity and rarity of occurrence.
The lack of measurable early disease markers and clinical outcomes further complicates the management of such disorders.Biologics presents a personalized and targeted method to treat NMDs and is a promising treatment class.
An overview of the global clinical trial landscape for emerging Phase 1, 2, and 3 treatments revealed that Amyotrophic LateralAmyotrophic Lateral Sclerosis (ALS), Myasthenia GravisMyasthenia Gravis (MG), Duchenne Muscular Dystrophy (DMD), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Diabetic Neuropathy (DN), and Spinal Muscular Atrophy (SMA) are the key hotspots for clinical studies.
These indications are likely to witness new drug developments.
Frost & Sullivan’s research, “Emerging Therapeutics for Rare Neuromuscular Diseases: A Pipeline Analysis†explores emerging biologics across these six NMDs.Key biologics emerging for these rare NMDs include stem cell therapies, other cell-based treatments, gene therapies, RNA therapeutics, immunotherapies, and other protein/peptide-based treatments.
There were 3 recent US FDA approvals for NMD RNA therapies: Nusinersen for SMA and Eteplirsen for DMD in 2016, and Golodirsen for DMD in 2019.Furthermore, Sarepta’s Casimersen for DMD and argenx’s efgartigimod for MG were approved as recently as 2021.
Biologics have opened doors for ground-breaking disease-modifying treatments and will transform the quality of life for patients across the world.While biologics may appear to cost more than small molecule treatments, they provide a personalized and, in some cases, the only treatment option.
They can also be less expensive than lifetime treatment costs for certain rare NMDs.
For example, Zolgensma’s $2.1 million price tag (approximate) is still lower than the standard medical costs incurred for SMA patients in a lifetime.
Furthermore, the evolving payer landscape is likely to get more standardized in the coming years to offer greater access to biologicals.
Therefore, biologics are suitably poised to transform the rare NMD landscape with personalized and targeted treatment strategies and will provide life-saving treatment options for fatal neuromuscular conditions.Key Points DiscussedWhat are the key emerging biologics for NMDs with high clinical activity?What are the key drivers or challenges for biologics development across NMDs?How do venture funding and patent landscapes look for NMD biologics?Who are the key industry participants developing biologics for NMDs?What are the clinical trends emerging across each biologic category for NMDs?Which biologic categories provide promising growth opportunities for NMD management?
Read the full report: https://www.reportlinker.com/p06368651/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.